PARP (Poly ADP-ribose Polymerase) Inhibitors Market Overview
As per Econ Market Research analysis, the Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market valuation stood at US$ 6.41 Billion in 2026 and is expected to reach US$ 14.15 Billion by 2035, growing at a steady CAGR of 9.2% from 2026 to 2035. 2025 serves as the base year.
PARP inhibitors are a class of drugs designed to interfere with the activity of poly ADP-ribose polymerase enzymes, which play a crucial role in DNA repair. The primary purpose of these inhibitors is to selectively target cancer cells, particularly those with deficiencies in the BRCA genes, as they rely heavily on the PARP pathway for DNA repair. This innovative therapeutic approach has gained substantial attention in the oncology field, with applications extending across various cancer types.
The market for PARP inhibitors has witnessed significant growth due to the increasing incidence of cancer globally and the continuous advancements in precision medicine. These inhibitors have shown promising results in the treatment of ovarian, breast, and prostate cancers, among others. The market',s expansion is further fuelled by ongoing research and development activities, with pharmaceutical companies actively investing in novel PARP inhibitors and combination therapies to enhance treatment efficacy.
PARP (Poly ADP-ribose Polymerase) Inhibitors Dynamics
One major factor driving the need for novel treatments like PARP inhibitors is the rising incidence of cancer in the world. The positive trajectory of the market is attributed to advancements in precision medicine and the growing comprehension of genetic factors that influence cancer susceptibility. Notably, the widespread occurrence of BRCA gene mutations, linked to diverse forms of cancer, stimulates the uptake of PARP inhibitors, given their notable effectiveness in treating BRCA-mutated cancers.
A significant dynamic is the continuous research and development that pharmaceutical companies engage in to improve the therapeutic profile of currently available PARP inhibitors and create new compounds. Industry participants can share resources and expertise through strategic collaborations and partnerships, which promote innovation and increase market competitiveness. The approval of new indications and formulations influences market expansion, and regulatory dynamics are crucial.
However, the market faces challenges such as high development costs, which may impede the pace of innovation. Patent expirations pose threats to established players, opening opportunities for generic competition. Additionally, concerns regarding potential side effects and the need for robust clinical evidence continue to shape the risk-benefit profiles of PARP inhibitors. Despite these challenges, the overall market dynamics remain positive, driven by a strong commitment to addressing unmet medical needs in oncology and a continuous focus on improving patient outcomes through targeted therapies.
PARP (Poly ADP-ribose Polymerase) Inhibitors Drivers
Increasing Incidence of Cancer and Genetic Factors
The market for PARP inhibitors is significantly influenced by the rising incidence of cancer worldwide. Since cancer is still the primary cause of morbidity and death, there is an increasing need for efficient, targeted treatments like PARP inhibitors. Furthermore, the use of PARP inhibitors is accelerated by the discovery of genetic variables, specifically mutations in the BRCA gene, associated with a variety of malignancies. These inhibitors have been shown to be more effective in tumours that lack DNA repair mechanisms, which makes them an essential part of the treatment regimen for some types of cancer. Finding patient populations that will benefit most from PARP inhibitor therapies is made easier by our growing understanding of the molecular causes of cancer.
Advancements in Precision Medicine and Personalized Therapeutics
The development and use of PARP inhibitors are motivated by the continuous developments in precision medicine. PARP inhibitors provide an individualised approach that is consistent with the tenets of personalised therapeutics, with an emphasis on customising treatments based on unique patient characteristics. The overall effectiveness of PARP inhibitors is increased by the capacity to identify patients with particular genetic mutations and match them with customised treatments.
Pharmaceutical companies are encouraged to invest in the development of next-generation PARP inhibitors and combination therapies as a result of this paradigm shift towards personalised medicine, which also improves patient outcomes. The integration of PARP inhibitors into precision medicine approaches is further supported by the changing landscape of molecular diagnostics.
Restraints:
High Development Costs and Market Competition
One of the main obstacles to the market',s expansion is the high expense of PARP inhibitor research, development, and clinical trials. Due to the intricate nature of cancer treatments, lengthy and expensive testing procedures are necessary, which affects PARP inhibitors', general accessibility and affordability. Furthermore, the competitive environment makes it more difficult for pharmaceutical companies to make ends meet, which puts pressure on prices and may prevent new competitors from entering the market. These difficulties might slow down the rate of advancement and restrict the range of patients for whom PARP inhibitors are available.
Patent Expirations and Generic Competition
Existing PARP inhibitors face a constraint in the form of generic competition due to the impending threat of patent expirations. Generic versions of products may become available once patents expire, which result in price erosion and a possible loss of market could share for original manufacturers. This dynamic affects revenue streams and emphasises the necessity of ongoing innovation to keep one step ahead of generic competitors. To increase the market exclusivity of their PARP inhibitors and lessen the impact of generic alternatives, pharmaceutical companies must strategically use lifecycle management, such as obtaining new indications or formulations.
Opportunities:
Expansion of Indications and Combination Therapies
An opportunity lies in the exploration of new indications and combination therapies for PARP inhibitors. Beyond their established efficacy in breast and ovarian cancers, ongoing research opens avenues for expanding the use of PARP inhibitors in other cancer types. Additionally, combining PARP inhibitors with other targeted agents or traditional chemotherapy offers the potential for synergistic effects, enhancing overall treatment outcomes. Pharmaceutical companies have the opportunity to invest in clinical trials to demonstrate the broader utility of PARP inhibitors, thereby capturing new market segments and increasing the therapeutic value of these drugs.
Segment Overview
By Drug Types
The market segments based on drug types include Talazoparib, Veliparib, Olaparib, and others. Talazoparib, a potent PARP inhibitor, has shown efficacy in various cancers, particularly breast cancer. Veliparib is recognized for its potential in combination therapies, enhancing the effectiveness of standard treatments. Olaparib, one of the pioneering PARP inhibitors, is widely used across multiple cancer indications. The ",others", category encompasses emerging PARP inhibitors, showcasing the industry',s commitment to innovation and expanding treatment options.
By Indication Types
The indication types segment encompasses Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, and others. PARP inhibitors have gained prominence in ovarian cancer treatment, especially in patients with BRCA mutations. Fallopian tube cancer, closely related to ovarian cancer, presents another target for PARP inhibitor therapies. Breast cancer, with its diverse subtypes, benefits from the precision of PARP inhibitors in cases with specific genetic alterations. The ",others", category denotes the potential for broader applications in various cancer types as research continues to uncover new opportunities.
By End-Users
End-users in the PARP inhibitors market include Hospitals, Homecare, Specialty Clinics, and others. Hospitals serve as major distribution points for PARP inhibitors, offering comprehensive cancer care. Homecare settings provide opportunities for patients to receive treatment in the comfort of their homes, promoting convenience. Specialty clinics, with their focus on oncology, play a crucial role in the administration of PARP inhibitors. The ",others", category may include academic medical centers or research institutions contributing to patient care and advancements in PARP inhibitor therapies.
By Distribution Channels
The distribution channels segment involves Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and others. Hospital pharmacies are central in dispensing PARP inhibitors within healthcare facilities. Online pharmacies offer a convenient option for patients to access these medications. Retail pharmacies serve as community-based outlets for PARP inhibitor distribution. The others category might include specialty distributors or collaborative distribution models aiming to optimize accessibility and patient adherence to PARP inhibitor therapies.
PARP (Poly ADP-ribose Polymerase) Inhibitors Overview by Region
North America, comprising the United States and Canada, dominates the market owing to advanced healthcare facilities, high cancer incidence rates, and early adoption of innovative therapies. The region is a hub for pharmaceutical research and development, fostering a competitive environment among key market players. Additionally, regulatory approvals for PARP inhibitors in various indications contribute to the robust market growth in North America.
In Europe, countries such as the United Kingdom, Germany, and France play a pivotal role in the PARP inhibitors market. The European Medicines Agency (EMA) approvals and collaborations with research institutions drive advancements in the understanding of genetic factors influencing cancer, influencing the adoption of PARP inhibitors. The region',s emphasis on personalized medicine and well-established healthcare systems further supports the integration of these inhibitors into standard cancer treatment protocols.
The Asia-Pacific region is witnessing significant growth, propelled by rising cancer incidences, improving healthcare infrastructure, and increasing awareness of advanced cancer therapies. Countries like China and Japan are key contributors, with a growing focus on precision medicine and the expansion of pharmaceutical research activities. Strategic partnerships between international pharmaceutical companies and local entities aim to enhance market access and capitalize on the region',s untapped potential.
PARP (Poly ADP-ribose Polymerase) Inhibitors Market Competitive Landscape
Leading players such as AstraZeneca, GlaxoSmithKline, Pfizer, and Clovis Oncology dominate the market with their well-established PARP inhibitor portfolios. AstraZeneca',s Olaparib, marketed as Lynparza, has been a trailblazer in the field, securing approvals across various cancer indications, including ovarian and breast cancers. GlaxoSmithKline',s Zejula (Niraparib) has also garnered attention for its efficacy in ovarian cancer, while Pfizer',s Talzenna (Talazoparib) demonstrates significant potential, especially in breast cancer treatment.
The competitive landscape is marked by strategic collaborations and partnerships aimed at expanding product portfolios and accessing new markets. AstraZeneca, for instance, has engaged in collaborations with Merck to explore the synergistic effects of combining PARP inhibitors with immunotherapies. Clovis Oncology has strategically focused on label expansions and clinical trials to enhance the therapeutic applications of its PARP inhibitor, Rubraca (Rucaparib).
PARP (Poly ADP-ribose Polymerase) Inhibitors Market Competitive Landscape Leading Companies:
AstraZeneca
GlaxoSmithKline plc
Pfizer Inc.
Clovis Oncology
Merck &, Co., Inc.
AbbVie Inc.
Johnson &, Johnson
Eisai Co., Ltd.
BeiGene
Jiangsu Hengrui Medicine Co., Ltd.
PARP (Poly ADP-ribose Polymerase) Inhibitors Recent Developments
Feb 2023, Pfizer has reported positive outcomes from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor. The study, conducted in combination with XTANDI (enzalutamide), reveals a statistically significant and clinically meaningful enhancement in radiographic progression-free survival (rPFS) when compared to a placebo plus XTANDI. This improvement is observed in men diagnosed with metastatic castration-resistant prostate cancer (mCRPC), regardless of the presence of homologous recombination repair (HRR) gene mutations.
PARP (Poly ADP-ribose Polymerase) Inhibitors Report Segmentation
PARP (Poly ADP-ribose Polymerase) Inhibitors Market Segmentation
| Segment Category | Segment Values |
|---|---|
| Drug Type |
|
| Indication |
|
| Distribution Channel |
|
Key Players
- AstraZeneca
- Merck and Co.
- GSK (Tesaro)
- Pfizer
- Clovis Oncology
- AbbVie
- Johnson and Johnson
Table of Contents
1. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET–REPORT OVERVIEW
- 1.1. SCOPE OF THE REPORT
- 1.2. MARKET SEGMENT ANALYSIS
- 1.3. REGULATORY SCENARIO BY REGION/COUNTRY
- 1.4. MARKET INVESTMENT SCENARIO STRATEGIC
- 1.5. MARKET ANALYSIS BY BY DRUG TYPE (USD MILLION)
- 1.5.1 GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY BY DRUG TYPE (2026-2035)
- 1.5.2 OLAPARIB
- 1.5.3 NIRAPARIB
- 1.5.4 RUCAPARIB
- 1.5.5 TALAZOPARIB
- 1.6. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY BY DRUG TYPE IN 2026 & 2035
- 1.7. MARKET ANALYSIS BY BY INDICATION (USD MILLION)
- 1.7.1 GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY BY INDICATION (2026-2035)
- 1.7.2 OVARIAN CANCER
- 1.7.3 BREAST CANCER
- 1.7.4 PROSTATE CANCER
- 1.7.5 PANCREATIC CANCER
- 1.8. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY BY INDICATION IN 2026 & 2035
- 1.9. MARKET ANALYSIS BY BY DISTRIBUTION CHANNEL (USD MILLION)
- 1.9.1 GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY BY DISTRIBUTION CHANNEL (2026-2035)
- 1.9.2 HOSPITAL PHARMACIES
- 1.9.3 RETAIL PHARMACIES
- 1.9.4 ONLINE PHARMACIES
- 1.10. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY BY DISTRIBUTION CHANNEL IN 2026 & 2035
2. DRIVER RESTRAINT CHALLENGE AND OPPORTUNITIES OF PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET
- 2.1. DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
- 2.1.1 MARKET DRIVER ANALYSIS
- 2.1.2 MARKET RESTRAINT ANALYSIS
- 2.1.3 MARKET OPPORTUNITY
- 2.2. MARKET CHALLENGES
3. GLOBAL GROWTH TRENDS
- 3.1. INDUSTRY TRENDS
- 3.1.1 SWOT ANALYSIS
- 3.1.1.1 Strengths
- 3.1.1.2 Weaknesses
- 3.1.1.3 Opportunities
- 3.1.1.4 Threats
- 3.1.2 PESTEL ANALYSIS
- 3.1.2.1 Political Landscape
- 3.1.2.2 Economic Landscape
- 3.1.2.3 Social Landscape
- 3.1.2.4 Technological Landscape
- 3.1.2.5 Environmental Landscape
- 3.1.2.6 Legal Landscape
- 3.1.3 PORTER'S FIVE FORCES ANALYSIS
- 3.1.3.1 Bargaining Power of Suppliers
- 3.1.3.2 Bargaining Power of Buyers
- 3.1.3.3 Threat of Substitute
- 3.1.3.4 Threat of New Entrant
- 3.1.3.5 Competitive Rivalry
- 3.1.1 SWOT ANALYSIS
- 3.2. POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4. POST COVID ANALYSIS
- 4.1. COVID V ANALYSIS
- 4.2. COVID U ANALYSIS
- 4.3. COVID L ANALYSIS
- 4.4. COVID W ANALYSIS
5. COMPANIES ANALYSIS
- 5.1. PLAYERS COVERED: RANKING BY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET REVENUE
- 5.2. TOP COMPANIES MARKET SHARE (%)
6. EXECUTIVE SUMMARY
7. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET FORECAST, 2022-2035, (USD MILLION)
- 7.1. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET REVENUE AND MARKET SHARE BY REGIONS
- 7.2. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY REGION (2022-2029)
- 7.3. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY REGION (2030-2035)
- 7.3.1.1 North America
- 7.3.1.2 Europe
- 7.3.1.3 Asia Pacific
- 7.3.1.4 Latin America
- 7.3.1.5 Middle East & Africa
8. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 8.1. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 8.2. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 8.3. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 8.3.1.1 United States
- 8.3.1.2 Canada
- 8.3.1.3 Mexico
9. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 9.1. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 9.2. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 9.3. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 9.3.1.1 United Kingdom
- 9.3.1.2 Germany
- 9.3.1.3 France
- 9.3.1.4 Spain
- 9.3.1.5 Italy
- 9.3.1.6 Rest of Europe
10. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 10.1. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 10.2. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 10.3. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 10.3.1.1 China
- 10.3.1.2 India
- 10.3.1.3 Japan
- 10.3.1.4 Australia
- 10.3.1.5 South Korea
- 10.3.1.6 Rest of Asia Pacific
11. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 11.1. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 11.2. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 11.3. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 11.3.1.1 Saudi Arabia
- 11.3.1.2 South Africa
- 11.3.1.3 Rest of MEA
12. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 12.1. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 12.2. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 12.3. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 12.3.1.1 Brazil
- 12.3.1.2 Argentina
- 12.3.1.3 Rest of Latin America
13. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SEGMENT BY BY DRUG TYPE, (USD MILLION)
- 13.1. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.2. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.3. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.4. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.5. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.6. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.7. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.8. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.9. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.10. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
- 13.11. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2022-2029)
- 13.12. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DRUG TYPE (2030-2035)
13. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SEGMENT BY BY INDICATION, (USD MILLION)
- 13.13. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.14. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.15. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.16. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.17. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.18. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.19. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.20. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.21. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.22. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.23. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.24. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
13. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SEGMENT BY BY DISTRIBUTION CHANNEL, (USD MILLION)
- 13.25. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.26. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.27. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.28. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.29. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.30. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.31. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.32. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.33. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.34. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
- 13.35. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2022-2029)
- 13.36. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET AND MARKET SHARE BY BY DISTRIBUTION CHANNEL (2030-2035)
14. COMPANY PROFILES
- 14.1. ASTRAZENECA
- 14.1.1 COMPANY DETAIL
- 14.1.2 FINANCIALS (USD MILLIONS)
- 14.1.3 PRODUCT SUMMARY
- 14.1.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.2. MERCK
- 14.2.1 COMPANY DETAIL
- 14.2.2 FINANCIALS (USD MILLIONS)
- 14.2.3 PRODUCT SUMMARY
- 14.2.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.3. CO.
- 14.3.1 COMPANY DETAIL
- 14.3.2 FINANCIALS (USD MILLIONS)
- 14.3.3 PRODUCT SUMMARY
- 14.3.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.4. GSK (TESARO)
- 14.4.1 COMPANY DETAIL
- 14.4.2 FINANCIALS (USD MILLIONS)
- 14.4.3 PRODUCT SUMMARY
- 14.4.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.5. PFIZER
- 14.5.1 COMPANY DETAIL
- 14.5.2 FINANCIALS (USD MILLIONS)
- 14.5.3 PRODUCT SUMMARY
- 14.5.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.6. CLOVIS ONCOLOGY
- 14.6.1 COMPANY DETAIL
- 14.6.2 FINANCIALS (USD MILLIONS)
- 14.6.3 PRODUCT SUMMARY
- 14.6.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.7. ABBVIE
- 14.7.1 COMPANY DETAIL
- 14.7.2 FINANCIALS (USD MILLIONS)
- 14.7.3 PRODUCT SUMMARY
- 14.7.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.8. JOHNSON
- 14.8.1 COMPANY DETAIL
- 14.8.2 FINANCIALS (USD MILLIONS)
- 14.8.3 PRODUCT SUMMARY
- 14.8.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.9. JOHNSON
- 14.9.1 COMPANY DETAIL
- 14.9.2 FINANCIALS (USD MILLIONS)
- 14.9.3 PRODUCT SUMMARY
- 14.9.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
15. CONCLUSION
16. REFERENCE LINK
17. APPENDIX
- 17.1. METHODOLOGY
- 17.2. RESEARCH DATA SOURCE
- 17.2.1 SECONDARY DATA
- 17.2.2 KEY DATA FROM SECONDARY
- 17.2.3 PRIMARY DATA
- 17.2.4 KEY DATA FROM PRIMARY
- 17.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
- 17.2.6 MARKET ESTIMATION
- 17.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
- 17.2.8 LEGAL DISCLAIMER
18. RESEARCH SCOPE
LIST OF TABLES
- TABLE 1. MARKET SEGMENT
- TABLE 2. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET GROWTH RATE BY BY DRUG TYPE (2026-2035)
- TABLE 3. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET GROWTH RATE BY BY INDICATION (2026-2035)
- TABLE 4. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET GROWTH RATE BY BY DISTRIBUTION CHANNEL (2026-2035)
- TABLE 5. COMPANY'S RANK BY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET REVENUE
- TABLE 6. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET — MARKET SNAPSHOT & KEY BUYING CRITERIA, 2026–2035
- TABLE 7. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 8. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 9. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY REGION, USD MILLION (2022-2029)
- TABLE 10. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY REGION, (2022-2029)
- TABLE 11. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY REGION, USD MILLION (2030-2035)
- TABLE 12. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY REGION, (2030-2035)
- TABLE 13. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 14. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 15. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 16. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 17. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 18. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 19. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 20. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 21. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 22. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 23. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2022-2029)
- TABLE 24. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 25. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2030-2035)
- TABLE 26. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 27. UNITED STATES PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 28. UNITED STATES PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 29. CANADA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 30. CANADA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 31. MEXICO PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 32. MEXICO PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 33. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2022-2029)
- TABLE 34. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 35. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2030-2035)
- TABLE 36. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 37. UNITED KINGDOM PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 38. UNITED KINGDOM PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 39. GERMANY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 40. GERMANY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 41. FRANCE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 42. FRANCE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 43. SPAIN PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 44. SPAIN PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 45. ITALY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 46. ITALY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 47. REST OF EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 48. REST OF EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 49. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2022-2029)
- TABLE 50. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 51. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2030-2035)
- TABLE 52. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 53. CHINA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 54. CHINA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 55. INDIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 56. INDIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 57. JAPAN PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 58. JAPAN PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 59. AUSTRALIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 60. AUSTRALIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 61. SOUTH KOREA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 62. SOUTH KOREA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 63. REST OF ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 64. REST OF ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 65. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2022-2029)
- TABLE 66. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 67. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2030-2035)
- TABLE 68. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 69. SAUDI ARABIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 70. SAUDI ARABIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 71. SOUTH AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 72. SOUTH AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 73. REST OF MEA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 74. REST OF MEA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 75. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2022-2029)
- TABLE 76. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 77. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY COUNTRY, (2030-2035)
- TABLE 78. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 79. BRAZIL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 80. BRAZIL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 81. ARGENTINA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 82. ARGENTINA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 83. REST OF LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2022-2029)
- TABLE 84. REST OF LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (USD MILLION) (2030-2035)
- TABLE 85. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 86. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 87. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 88. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 89. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 90. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 91. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 92. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 93. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 94. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 95. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2022-2029)
- TABLE 96. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DRUG TYPE, USD MILLION (2030-2035)
- TABLE 97. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 98. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 99. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 100. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 101. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 102. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 103. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 104. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 105. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 106. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 107. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 108. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 109. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 110. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 111. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 112. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 113. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 114. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 115. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 116. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 117. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 118. MIDDLE EAST & AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
- TABLE 119. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2022-2029)
- TABLE 120. SOUTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET BY BY DISTRIBUTION CHANNEL, USD MILLION (2030-2035)
LIST OF FIGURES
- FIGURE 1. MARKET OVERVIEW
- FIGURE 2. REGIONAL SHARE
- FIGURE 3. MARKET REVENUE (USD MILLION)
- FIGURE 4. DROC OF PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET ANALYSIS
- FIGURE 5. SWOT ANALYSIS
- FIGURE 6. PESTEL ANALYSIS
- FIGURE 7. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 8. COVID V, U, W AND L ANALYSIS
- FIGURE 9. LEADING COMPANIES
- FIGURE 10. REGIONAL ANALYSIS
- FIGURE 11. COUNTRY ANALYSIS
- FIGURE 12. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 13. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 14. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION), BY REGION
- FIGURE 15. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2026), BY REGION
- FIGURE 16. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION), BY REGION
- FIGURE 17. GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2035), BY REGION
- FIGURE 18. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 19. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 20. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 21. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 22. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 23. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 24. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 25. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 26. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 27. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 28. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 29. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 30. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 31. NORTH AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 32. UNITED STATES PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 33. UNITED STATES PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 34. CANADA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 35. CANADA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 36. MEXICO PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 37. MEXICO PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 38. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 39. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 40. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 41. EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 42. UNITED KINGDOM PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 43. UNITED KINGDOM PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 44. GERMANY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 45. GERMANY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 46. FRANCE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 47. FRANCE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 48. SPAIN PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 49. SPAIN PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 50. ITALY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 51. ITALY PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 52. REST OF EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 53. REST OF EUROPE PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 54. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 55. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 56. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 57. ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 58. CHINA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 59. CHINA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 60. INDIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 61. INDIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 62. JAPAN PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 63. JAPAN PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 64. AUSTRALIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 65. AUSTRALIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 66. SOUTH KOREA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 67. SOUTH KOREA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 68. REST OF ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 69. REST OF ASIA PACIFIC PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 70. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 71. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 72. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 73. MIDDLE EAST AND AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 74. SAUDI ARABIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 75. SAUDI ARABIA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 76. SOUTH AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 77. SOUTH AFRICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 78. REST OF MEA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 79. REST OF MEA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 80. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 81. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 82. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 83. LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 84. BRAZIL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 85. BRAZIL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 86. ARGENTINA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 87. ARGENTINA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
- FIGURE 88. REST OF LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2022-2029), (USD MILLION)
- FIGURE 89. REST OF LATIN AMERICA PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS MARKET, (2030-2035), (USD MILLION)
Research Methodology
Our research methodology is carefully designed to deliver the clients with the most accurate, relevant, and actionable market insights to enable clear decision-making and leveraging of opportunities in the markets. We believe consistency, depth in analysis, and a tailored approach in each report are what help set us apart in the industry. The research methodology is based on an integrating research process consisting of in-depth data collection, a complex analysis, and a stringent validation system.
Data Collection
Data collection forms the basis of our study and gathers diverse authentic data to build the basis for deeper study in terms of market trends, competitive landscape, and growth prospects. Data collection takes place through two channels of main activities as follows:
Primary Data Collection
Primary data collection allows collecting real-time and firsthand information from market participants. This is an engagement process conducted by our team with other industry stakeholders, where a much deeper insight than any published data is pursued. This process includes:
- Direct Interviews – We interview the key decision-makers such as CEOs, product managers, innovation heads, and marketing directors to gather both qualitative and quantitative information. The questionnaire covers emerging trends, customer preferences, regulatory impact, and competitors’ strategies.
- Demand and Supply-Side Inputs – Interviews and surveys with supply and demand-side stakeholders provide a balanced view of prevailing market conditions, including feedback from manufacturers, distributors, suppliers, and end-users.
- Expert Opinions – Consultations with industry experts and domain specialists provide insights into future market direction, risks, and opportunities.
- Focus Groups and Online Surveys – Focus groups and surveys are used to understand consumer preferences and adoption probability of new products or services.
Primary research forms the core of our data validation process by offering direct insights into the market, addressing limitations in secondary data, and allowing for an adaptable research process.
Secondary Data Collection
Secondary research serves as a robust foundation for understanding market context, historical data, and larger trends. It involves systematic gathering of existing information from verified sources.
- Industry Reports and Publications – Market reports, white papers, and case studies from credible sources provide a broad view of the market landscape and key players.
- Government and Public Records – Data from government agencies and regulatory bodies helps analyze economic factors and policy impacts.
- News and Media Outlets – Monitoring news articles, press releases, and media reports keeps us updated on market developments and M&A activity.
- Proprietary and Paid Databases – Databases such as Bloomberg, Factiva, D&B Hoovers, and Thomson Reuters provide validated and cross-referenced data.
- Financial Reports and SEC Filings – Financial statements, annual reports, and investor presentations provide insights into revenue structures and profitability.
This combination of primary and secondary data sources enables us to provide a comprehensive view of the market, supported by authenticated information across multiple sources.
Data Analysis Techniques
With the data collected, we initiate a rigorous analysis phase. We analyze market dynamics, growth patterns, and future performance using analytical models and statistical tools.
Top-Down and Bottom-Up Market Sizing Approaches
- Top-Down Approach – Starts with global market size and distributes it across segments using macro-level trends and established proportions.
- Bottom-Up Approach – Aggregates company-level and country-level revenue data to build regional and global market estimates.
These two approaches are cross-validated to remove inconsistencies and ensure accurate market estimation.
Forecasting Models and Market Dynamics Analysis
- Time-Series Analysis – Models historical trends, seasonality, and demand cycles.
- Econometric and Judgmental Forecasting – Combines economic models with expert-driven adjustments.
- Delphi Method – Uses iterative expert input to generate balanced market forecasts.
Data Triangulation and Validation
- Multi-source cross-verification of all data points
- Use of quantitative and qualitative validation techniques
- Sample validation through expert and stakeholder feedback
Market Analysis and Sizing Estimation
- Detailed segmentation analysis
- Competitive landscape evaluation
- Revenue modeling using TAM, SAM, and SOM frameworks
Quality Assurance and Final Review
- Data accuracy and consistency checks
- Content, language, and structure review
- Client-specific customization and refinement
Continuous Improvement in Methodology
We continuously refine our research methodologies based on evolving market conditions, client feedback, and technological advancements. This ensures our research remains accurate, relevant, and aligned with industry standards.
PARP (Poly ADP-ribose Polymerase) Inhibitors Market Report Scope & Segmentation
| Attributes | Details |
|---|---|
| Market Size (Current)Current market valuation | US$ 6.41 Billion in 2026 |
| Market Size (Forecast)Projected market valuation | US$ 14.15 Billion in 2035 |
| Growth RateCompound Annual Growth Rate | CAGR of 9.2% from 2026 to 2035 |
| Forecast PeriodAnalysis timeline | 2026 – 2035 |
| Base YearReference year for analysis | 2025 |
| Historical Data AvailablePast market data availability | Yes |
| Regional ScopeGeographical coverage | Global |
| Segments CoveredMarket segments analyzed | By Drug Type
By Indication
By Distribution Channel
|
Leading companies covered in this report
- AstraZeneca
- Merck and Co.
- GSK (Tesaro)
- Pfizer
- Clovis Oncology
- AbbVie
- Johnson and Johnson
Frequently Asked Questions
Common questions about this report
The study period covers historical insights and forecast projections for the period 2026-2035.
The global PARP (Poly ADP-ribose Polymerase) Inhibitors Market market is expected to grow at a CAGR of 9.2% during the forecast period 2026-2035.
The report offers comprehensive market segmentation analysis across key categories and sub-segments relevant to the industry, along with regional and competitive insights.
The market is projected to reach 14.15 Billion by 2035.
Key players in the PARP (Poly ADP-ribose Polymerase) Inhibitors Market include AstraZeneca, Merck and Co., GSK (Tesaro), Pfizer, Clovis Oncology, AbbVie, and Johnson and Johnson.
North America, Europe, and Asia Pacific are key regions covered in the report, including regional trends, market share, and growth opportunities.
Growing demand, technological advancements, changing consumer preferences, and increasing investments are some of the major factors supporting the growth of the PARP (Poly ADP-ribose Polymerase) Inhibitors Market market.
Yes, the report includes company profiling, competitive landscape analysis, strategic developments, mergers & acquisitions, product launches, and market positioning of leading industry participants.
The report is prepared using a combination of primary research, secondary research, expert interviews, industry databases, company annual reports, and proprietary market analysis models.
Yes, report customization options are available based on specific business objectives, geographic focus, competitive benchmarking requirements, and additional market segmentation needs.
Yes, the report is available in both PDF and Excel formats. The Excel file includes all market data tables, forecasts, and segment-wise data for easy analysis.
Yes, you can request a free sample report which includes an overview, table of contents, and sample data pages to help you evaluate the report before making a purchase decision.
About the Author
Market research expert with years of industry experience
